Noonan's syndrome (NS), LEOPARD syndrome (LS) and Noonan's-like/multiple giant cell lesion syndrome (NL/MGCLS) are clinically and genetically related conditions. The phenotype of these disorders is mainly characterised by short stature, facial dysmorphims, and congenital heart defects, in particular pulmonary valve stenosis and hypertrophic cardiomyopathy. In addition, individuals with LS present cafè-au-lait spots and multiple lentigines, while NL/MGCLS patients show giant cell lesions of bones, joints and/or soft tissues. These disorders are often due to missense mutations of the PTPN11 gene, encoding for SHP2, a protein tyrosine phosphatase involved in RAS signalling. Here we propose clinical and molecular guidelines for baseline and follow-up management of affected individuals, with the aim of advising clinicians and scientists involved in the management of patients with NS and related disorders.
|Number of pages||11|
|Journal||Italian Journal of Pediatrics|
|Publication status||Published - 2006|
- LEOPARD syndrome
- Noonan's syndrome
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health